Supplementary Figure S9 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Western blots for models WT-12 and BT-16. Antitumor activity of vobra duo and SYD988 in WT-12 (A) and BT-16 (B) xenograft models (to support Fig. 4C and D). Vobra duo (6 mg/kg, IP) and SYD988 (6 mg/kg, IP) were each administered once on day 1. Tumors were collected at 6 hours and 48 hours after treatment. Western blot analysis was performed on tumor lysates using antibodies against B7-H3 and GAPDH (loading control).